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I. Introduction 
Allergic rhinitis is one of the most common health problems in many countries, 
because it is a high-cost, high-prevalence disease, affecting about 15-30% of the population. 
The number of the patients with allergic rhinitis is still increasing, especially in the well-
developed, industrialized countries [1]. Although it is not associated with severe morbidity 
and mortality, allergic rhinitis has a major effect on the quality of life. Its increasing 
prevalence, its impact on the individual quality of life and social costs [2, 3] and its role as a 
risk factor for asthma [4], underline the need for improved treatment options for this disorder. 
Allergic rhinitis is an inflammatory disorder of the nasal mucosa characterized by 
nasal itching, sneezing, nose running, nose blockage, itching of the nasal palate, itching of the 
eyes and of the external auditory canal, edema of the eyelids and occasionally loss of the 
sense of smell. In the case of seasonal or transitoric rhinitis pollens of different trees, grasses, 
flowers and weeds are responsible for developing of the clinical symptoms, which lasts for a 
few weeks or months depending on the flowering of the plants. The severity of the symptoms 
mainly depends on the pollen count, but non-specific, environmental factors (such as air 
pollution), the physical and psychical condition of the patient can also influence it. The pollen 
season can be divided into three periods in Hungary. The first one is the spring season 
(March-April), when the trees and bushes bloom. The next one is when the grass and grain 
bloom (May-June) and, finally, the end of summer and fall, with the blooming of the ragweed 
and other weeds. This last season is when the symptoms are the most acute and the number of 
the patients is the highest, too. House-dust mite, animal hair and feather, mould spores are 
responsible for developing of perennial allergic rhinitis, which exists throughout the entire 
year. It has the same clinical symptoms such as seasonal allergic rhinitis, but the main 
symptom is the nasal blocking, and its frequent complication is sinusitis. 
The etiology of allergy is multifactorial, it is genetically determined, but environmental 
factors also play an important role in the development of the typical symptoms. The 
inflammation of the nasal mucosa is frequently induces the inflammatory condition of the 
paranasal sinuses (rhinosinusitis). 
The inflammation is a type I, or immediate hypersensitivity reaction of the nasal 
mucosa that arises in consequence of an allergen-immunoglobulin E (IgE) interaction in 
sensitized individuals [5]. The development of the disease is characterized by an initial 
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sensitization phase to a specific allergen, when no clinical symptoms are present. At later 
time-points the encounter of the same allergen by sensitized individuals is followed by the 
elicitation of an allergen specific immune response and the activation of effector mechanisms. 
Previous studies have established that a shift towards T-helper 2 (Th2) cells plays a role in the 
initiation and maintenance of the disease [6, 7], Eosinophils, mast cells and basophils are 
considered the effector cells of hay fever [8, 9]. Following an allergen challenge these cells 
release inflammatory mediators such as histamine, tryptase, leukotrienes, prostaglandins, 
cytokines and eosinophil cationic protein (ECP), which are responsible for most of the 
pathological processes occurring in the nasal mucosa [5, 9-11]. 
Elimination of the inhalative allergens -which are responsible for developing of hay 
fever- from the patient's environment is very difficult. For the treatment of the disease, well-
established pharmacological therapies are available. Locally and systematically applied 
antihistamines are widely used to block the released mediators from the increasing number of 
inflammatory cells in the nasal mucosa. Sodium cromoglycate is used to inhibit mediator 
release from inflammatory cells; locally and systematically applied corticosteroids are 
effective in blocking new mediator synthesis. New therapeutic options have recently become 
increasingly important, including leukotriene modifiers, anti-IgE antibodies, 
phosphodiesterase inhibitors and intranasal heparin, and there have been developments in 
appropriate allergen-specific immunotherapy [12]. However, the complete suppression of the 
clinical symptoms may not be achieved in most of the cases with the currently available 
drugs. The use of these drugs is controversial in special subsets of patients such as pregnant 
and breast-feeding women [13], and pharmacotherapy has a numerous side-effects, too. All of 
these characteristics of allergic rhinitis highlight the need for effective new treatment options. 
Phototherapy has a profound immunosuppressive effect [14-18], and the different 
phototherapeutic methods utilizing both ultraviolet (UV) and visible (VIS) light has been 
widely used for the therapy of various inflammatory skin diseases, including atopic dermatitis 
and psoriasis [19-21]. Initially, broadband UV light sources in the 290-320 nm UVB spectrum 
range (BB-UVB) were used for the treatment of allergic and non-allergic skin diseases. 
During the last few years, these light sources have been replaced with the more efficient 
narrow-band UVB light sources operating at 311 nm + 2 nm wavelength (NB-UVB) [12]. A 
new, highly effective laser-based phototherapy has been introduced recently for the treatment 
of different skin diseases based on the use of the 308 nm xenon chloride excimer laser 
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radiation. The "super narrow-band" 308 nm xenon chloride (XeCl) excimer laser has been 
found to be more effective than NB-UVB in inducing T cell apoptosis in vitro and is also 
clinically more effective for the treatment of an inflammatory skin disease, psoriasis [22-24]. 
These results now have been confirmed by other groups and the 308 nm excimer laser is 
currently widely used for the treatment of allergic and non-allergic skin diseases [25, 26] 
In addition ultraviolet A (UVA; 315-400 nm), psoralen plus UVA (PUVA), combined UVA-
UVB and high-dose UVA1 (340-400 nm) therapies are also essential in the dermatological 
practice. The major mechanisms of immunosuppression induced by the various forms of 
phototherapy in the skin involve apoptosis induction in infiltrating T cells, reduction in the 
number and function of Langerhans cells, and the induction of immunomodulatory cytokines 
such as IL-10 [16-18, 22, 27-34] 
Although the different atopic diseases, e.g. atopic dermatitis and allergic rhinitis, share many 
common pathogenetic factors, and there are a large number of phototherapeutic modalities for 
the treatment of atopic dermatitis, the use of UV-based therapies for the treatment of allergic 
rhinitis has never been reported. Therefore we were interested in whether phototherapy might 
also be effective for the treatment of allergic rhinitis. 
Skin prick test (SPT) is the most frequently used in vivo test for the diagnosis of 
immediate type allergic reaction identifying an allergen responsible for the development of an 
allergic disease such as hay fever. To perform SPT a drop of the suspected allergen solution is 
applied to a skin test area of the forearm. The upper layer of the skin is then pricked using a 
lancet to promote the penetration of the allergen through the epidermis. After 20 minutes the 
allergen is removed and the skin reaction is checked. If wheal (urtica) and/or skin reddening 
(flare reaction) is detected it suggests that the investigated allergen induced an IgE mediated 
allergic reaction. The size of the urtica/flare reaction reflects the severity of the allergic 
response. SPT is also used to assess the clinical efficacy of different drug treatments for 
allergic diseases, such as hay fever or asthma, since there is a good correlation between the 
suppression of the reaction in SPT and inhibition of the clinical symptoms [35, 36]. Based on 
these facts, it seemed reasonable to use SPT in order to test the efficacy of the different forms 
of phototherapy for the treatment of allergic rhinitis. We assumed that if phototherapy 
suppresses SPT reactions it may also be effective in inhibiting clinical symptoms of allergic 
rhinitis. 
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2. Aims 
2.1. In the first series of our study we tested the capacity of different wavelengths to inhibit 
the wheal formation in the SPT reaction. 
2.2. According to these results in the second series of our study we sought to investigate the 
effect of these different light sources in the treatment of allergic rhinitis and thus to identify 
the clinically most effective wavelengths, which combine the advantages of high efficacy and 
few side effects. 
3. Methods 
3.1. Investigation of the effect of different wavelengths on the immediate type 
hypersensitivity reaction in the skin 
3.1.1. Patients 
The study protocol was approved by the Human Investigation Review Board of the Szeged 
University. Informed consent was obtained from 51 patients with a history of at least two 
years of allergic rhinitis or allergic rhinoconjunctivitis (f:m=31:20, mean age=34.17 years) 
with skin types II/III. Patients discontinued taking any antiallergic treatment 2 weeks prior to 
the performance of SPTs. All patients had a positive SPT with a wheal formation of at least 
10.0 mm in diameter. 
3.1.2. Irradiation protocol 
Patients in group 1 (n = 7, f:m = 5:2, mean age: 21.85 years) received UVB irradiation. UVB 
source was 308 nm XeCl excimer laser (Lambda Physics LPX 105 E). The energy density of 
each light impulse was 5,5 mJ/cm2 with a duration of 15 ns, the frequency of the laser was 10 
Hz. The individual minimal erythema dose (MED) was determined by irradiating the skin in 
the gluteal region with increasing doses of XeCl excimer laser. We read the MED values 24 h 
after the irradiation. The mean MED was 364 mJ/cm2. After the MED measurements 4 cm2 
test areas on the volar forearm of each patient were irradiated with the XeCl laser, in dosages 
of 0.5 x MED, 1.0 x MED and 2.0 x MED. Twenty-four and 48 hours after the irradiation, 
SPTs were performed with the same antigen on both the irradiated and non-irradiated skin 
areas. 
Patients in group 2 (n=5, f:m=4:l, mean age: 39.4 years) received UVA irradiation. UVA 
source was Waldmann PUVA 4000 (Waldmann, Villingen, Germany, range:320-400 nm). On 
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the forearms of the patients 4 cm2 areas were irradiated in dosages of 0,5 J/cm2, 1 J/cm2, 2 
J/cm2 respectively. 24, 48 and 72 h after the irradiation, SPTs were performed with the same 
antigen on both the irradiated and non-irradiated skin areas. 
The volar forearm of the patients in group 3 (n=5, f:m=4:l, mean age: 39.4 years) was treated 
with a 0.15% solution of 8-methoxypsoralen (8-MOP) for 15 min prior to UVA irradiation 
(Waldmann, Villingen, Germany, range:320-400 nm). 24, 48 and 72 h after the irradiation, 
SPTs were performed with the same antigen on both the irradiated and non-irradiated skin 
areas. 
In group 4 (n=10, f:m=l:l, mean age: 38.3 years) we used combined UVA-UVB irradiation 
(Rhinolight-UVA-UVB, Hungary, range: 300-400 nm), the irradiation doses were 0.214 
J/cm2, 0.428 J/cm2, 0.642 J/cm2 and 0.856 J/cm2 with a duration of 45 s, 90 s, 135 s and 180 s 
respectively, the test areas were 15 mm in diameter. 24, 48 and 72 h after the treatment SPTs 
were performed on the irradiated and on non-irradiated, control skin areas. 
In group 5 (n=10. f:m=l:l, mean age: 38.3 years) we applied photosensitization with a 0.15% 
solution of 8-MOP for 15 minutes prior to UVA-UVB irradiation (Rhinolight UVA-UVB, 
Hungary, range: 300-400 nm), then the test areas of the volar forearm were irradiated with 
dosages of 0.214 J/cm2, 0.428 J/cm2, 0.642 J/cm2 and 0.856 J/cm2, respectively. 24, 48 and 
72 h after the treatment SPTs were performed on the irradiated and on non-irradiated, control 
skin areas. 
In group 6 seven patients were irradiated with increasing doses of visible (VIS) light 
(Rhinolight-VIS, Hungary, range: 395-600 nm) in dosages of 2,4,6, 8 J/cm2, respectively. 
24 hours after the irradiation, SPTs were performed with the same antigen on both the 
irradiated and non-irradiated skin areas. 
In group 7 in 7 patients irradiation was performed with increasing doses of mixed UVB (5%), 
UVA (25%) and VIS (70%), referred to as mUV/VIS light (2, 4, 6 and 8 J/cm2) (Rhinolight-
mUV/VIS, Hungary, range: 310-600 nm). Measurements were performed with Scientech 
Vector H410 (Scientech Inc., Boulder, Colorado) and Jobin-Yvon H-20UV (Ocean Optics, 
RK Duiven, The Netherlands). 24 and 48 hours after the irradiation, SPTs were performed 
with the same antigen on both the irradiated and non-irradiated skin areas. 
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3.1.3. Skin prick test 
The SPT is a method that is widely used to investigate the immediate hypersensitivity reaction 
to a specific allergen in the skin [35]. SPTs were performed with recombinant allergens 
(Soluprick-Epipharm Allergie-Service GmbH). Ragweed, muggle, cat and dog hair antigens 
were used for the investigations. Twenty-micro litre aliquots of the test solutions were placed 
on the patients' forearms, with a distance of more than 3 cm between individual application 
points. Sterile 0.9% sodium chloride solution and histamine hydrochloride were used for 
control purposes. Reactions were recorded 20 min after testing and the wheal size was 
measured by digital planimetry. After determination of the individual sensitivity of each 
patient, for each individual one allergen was chosen that induced an "optimal" wheal of 
approximately 10 mm in diameter. SPT reactions were then examined with this antigen on the 
irradiated and non-irradiated control skin areas 24, 48 and 72 hours after irradiation. 
3.1.4. Statistical analysis 
To evaluate the effect of different wavelength irradiations on the development of allergen-
induced wheals, the size of the wheals that developed on the irradiated areas were compared 
with those on the non-irradiated control test areas. Differences in wheal size were analyzed 
statistically by means of repeated measures one-way ANOVA followed by Dunnett's post-
hoc test. If parametric ANOVA was not applicable we used Friedman repeated measures 
ANOVA, followed by Dunnett's post-hoc test. Differences were considered to be statistically 
significant at p< 0.05. 
3.2 Intranasal phototherapy 
3.2.1. Assessment of tolerability and efficacy of intranasal XeCl laser therapy in hay fever 
3.2.1.1. Patients 
Eighteen patients (f: m = 7:2, mean age: 44.89 years) were enrolled into the XeCl laser study. 
All of the patients suffered from severe, ragweed-induced hay fever that did not respond well 
to conventional antiallergic treatment, all had a history of rhinitis of at least 2 ragweed 
seasons. The diagnosis of allergic rhinitis was confirmed by positive SPT results to ragweed 
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(a wheal greater than 5 mm) and by measurement of the ragweed-specific IgE antibody level. 
Patients with significant nasal structural abnormalities, bronchial asthma, an upper respiratory 
tract infection within the past 2 weeks or a lower respiratory infection within 4 weeks prior to 
the start of the study were excluded. Further exclusion criteria were treatment with systemic 
corticosteroids within the previous 4 weeks, topical corticosteroids or cromolyn sodium 
within 2 weeks, antihistamines and decongestants within 1 week prior to the beginning of the 
study or immunotherapy in the past 2 years. During the study patients were not allowed to use 
any drugs. The patients were inrolled into two groups, and an open-label study was performed 
to assess the tolerability and the efficacy of the XeCl excimer laser in allergic rhinitis. The 
investigation was performed between 15 August and 20 September 2001, and the ragweed 
pollen counts were above 50/m3 in Szeged area throughout the study. Informed consent 
according to the Institutional Review Board of the Albert Szent-Györgyi Medical Center at 
the University of Szeged, was obtained from each individual before the start of the study. 
3.2.1.2. Low-dose XeCl laser treatment group 
The patients in group 1 (n = 10) received low-dose XeCl laser irradiation. The light source 
was a 308 nm XeCl excimer laser (Lambda Physics LPX 105 E). The energy density of each 
light impulse was 15.11 mJ/cm2 with a duration of 15 ns, with a laser repetition rate of 10 Hz. 
The MED of each patient was determined first by irradiating the skin in the gluteal region 
with different dosages (100-600 mJ/cm2) of the XeCl laser. The MED values were read off 
24 hours after the irradiation. The mean MED was 285 mJ/cm . The treatment of the nasal 
mucosa was performed by means of a special instrument for targeted phototherapy 
(Rhinolight handpiece, Rhinolight, Hungary) (Fig.l.), and started with a fluence of 0.25 x the 
individual MED. The handpiece of the instrument was introduced into the nasal cavity of the 
patients, and its distal end was carefully moved continuously in order to be able to irradiate 
homogenously large area of the nasal mucosa. Two treatments were given weekly for two 
weeks. After the first treatment, the dosage of the UV light was increased in steps of 0.125 x 
MED up to 0.625 x MED. The patients scored the severity of their clinical symptoms 
(sneezing, nasal itching, nose running, nasal blockage) on a 4-point scale once a day in a 
diary; 0 = no symptoms, 1 = mild, 2 = moderate and 3 = severe symptoms. The total nasal 
score (TNS) was calculated as the sum of the severity scores. All side effects observed during 
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the treatment were recorded. In the course of the study, the patients did not use any 
antiallergic drugs. 
3.2.1.3. Medium-dose XeCl laser treatment group 
The patients in group 2 (n = 8) received medium dose XeCl laser irradiation. The treatment of 
the nasal mucosa started with a fluence of 0.4 x MED, increased in steps of 0.125 x MED or 
to the individual tolerance level. Four treatments were given weekly for two weeks. The 
patients scored the severity of their clinical symptoms in the same way as in group 1. Again, 
all side effects were recorded during the treatment. 
3.2.2. Assessment of tolerability and efficacy of intranasal PUVA therapy in hay fever 
3.2.2.1. Patients 
Seventeen patients (f:m=13:4, mean:41.7 years) with severe ragweed-induced hay fever were 
enrolled into the study. Previously none of the subjects had responded well to any 
conventional antiallergic treatment and all had a history of rhinitis of at least 2 ragweed 
seasons. The diagnosis of allergic rhinitis was confirmed by positive SPT results to ragweed 
(a wheal greater than 5 mm) and by measurement of the ragweed-specific IgE antibody level. 
Patients with significant nasal structural abnormalities, bronchial asthma, an upper respiratory 
tract infection within the past 2 weeks or a lower respiratory infection within 4 weeks prior to 
the start of the study were excluded. Further exclusion criteria were treatment with systemic 
corticosteroids within the previous 4 weeks, topical corticosteroids or cromolyn sodium 
within 2 weeks, antihistamines or decongestants within 1 week prior to the beginning of the 
study or immunotherapy in the past 2 years. During the study patients were not allowed to 
use any drugs. An open study was performed to assess the efficacy and tolerability of the 
PUVA therapy in allergic rhinitis. Informed consent according to the Institutional Review 
Board of the Albert Szent-Györgyi Medical Center at the University of Szeged was obtained 
from each individual before the start of the study. 
3.2.2.2. PUVA treatment of the nasal cavity 
PUVA treatment (n=17) was performed with a nasal spray containing 8-MOP 2 min before 
irradiation of the nasal cavity with UV light (Rhinolight-PUVA, Szeged, Hungary). The 
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spectrum of this light source was between 305 and 440 nm with maximum at 365 nm. To 
determine the initial treatment dose, the minimal phototoxic dose (MPD) was determined on 
the patients' gluteal skin. The MPD is the lowest UV dose that induces erythema on the 
previously photosensitized skin. The MPD was determined by applying the photosensitizing 
drug (a 0.15% solution of 8-MOP) to the test areas 15 minutes prior to different dosages of 
UVA irradiation. The first UV dosage at which erythema developed 72 hours after UV 
treatment was regarded as the MPD of that patient. Treatment of the nasal mucosa was 
performed by means of a special instrument for targeted phototherapy (Rhinolight, Hungary), 
and started with a fluence of 0.5 x the individual MPD. Four treatments were given weekly 
for 3 weeks. After the first two treatments the UV light dosage was gradually increased in 
steps of 0.125 x MPD up to 1 x MPD. The patients scored the severity of their clinical 
symptoms (sneezing, nasal itching, nose running and nasal blockage) on a 4-point scale once 
a day in a diary; 0 = no symptoms, 1 = mild, 2 = moderate and 3 = severe symptoms. The 
TNS was calculated as the sum of the severity scores. All side-effects observed during the 
treatment were recorded. In the course of the study the patients did not use any antiallergic 
drugs. 
3.2.3. Intranasal phototherapy with mUV/VIS light 
3.2.3.1. Patients 
We conducted a randomized, double-blind study in 49 patients with a history of at least 2 
years of moderate to severe ragweed-induced allergic rhinitis that was not controlled by 
antiallergic drugs. Positive SPTs and an elevated level of ragweed-specific IgE antibody 
confirmed the diagnosis. The Human Investigation Review Board of the Szeged University 
had approved the protocol. All patients gave their written informed consent. We excluded 
potential subjects from the study if they had any significant nasal structural abnormalities; had 
asthma, perennial rhinitis or upper or lower respiratory infection within 4 weeks prior to the 
beginning of the study, or had used any of the following drugs: systemic corticosteroids 
within 4 weeks, topical corticosteroids within 2 weeks, membrane stabilizers within 2 weeks, 
antihistamines within one week, nasal decongestants within 3 days or immunotherapy 5 years 
prior to the beginning of the study. 
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The patients were enrolled after the beginning of the ragweed season, when the pollen counts 
were above 50/m3 in Szeged area. Seventy-two patients with allergic rhinitis were recruited to 
participate in the study. After the screening visit 23 patients were excluded because they did 
not meet the inclusion criteria. Forty-nine patients were randomly assigned to receive either 
mUV/VIS irradiation in the active treated group (25 patients) or low intensity visible light (1-
VIS) in the control group (24 patients). 
3.2.3.2. Treatment protocol with mUV/VIS light 
Each intranasal cavity was irradiated 3 times a week for 3 weeks either with increasing doses 
of mUV/VIS (starting dose 1.6 J/cm2 ) or with 1-VIS light (starting dose 0.06 J/cm2). 
Irradiations were performed with the same device (Rhinolight-mUV/VIS lamp, Hungary, 
range: 310-600 am). 1-VIS irradiation was obtained by using a Schott FG13 filter (Schott AG, 
Mainz, Germany). In the mUV/VIS group, the patients were treated with the same dose for 
two consecutive dates, every third treatment-day the dose was raised by 0.25 J/cm2, the top 
dose was 2.6 J/cm2, During the course of the investigation, the only rescue medication 
allowed was cetirizine. Each patient kept a diary of daily symptoms on a scale of 0 to 3 (0 
indicating no symptoms and 1, 2 and 3 indicating mild, moderate and severe symptoms, 
respectively) for nasal obstruction, nasal itching, rhinorrhoea and sneezing. An independent 
investigator examined the patients weekly and performed nasal lavages. At these weekly 
visits patients also scored their symptoms. TNS, a sum of scores for sneezing, rhinorrhoea, 
nasal itching and nasal obstruction, which is considered the most common and best 
established parameter for the clinical assessment of allergic rhinitis, was also calculated. 
Nasal obstruction was also evaluated by using acoustic rhinometry. At the end of the protocol, 
the overall efficacy of the therapy was assessed on a scale from 1 to 4 (with 1 corresponding 
to significant, 2 moderate, 3 slight and 4 no global improvement of symptoms). 
} 
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Fig. 1. Instrument used for the intranasal irradiation 
3.2.4. Statistical analysis 
The effects of intranasal phototherapy on the clinical symptoms were analyzed by the 
Wilcoxon's Sum of Ranks test, comparing the clinical scores at the beginning with those at the 
end of the treatment period. The all-available data approach was applied. All analyzed data 
correspond to pollen counts over 50/m3. A probability level p < 0.05 was considered to be a 
statistically significant difference. 
4. Results 
4.1. Effects of the different wavelength irradiations on the immediate type 
hypersensitivity reaction in the skin 
4.1.1. Effects of XeCl laser irradiation on the SPT reaction 
The XeCl excimer laser induced a dose-dependent inhibition of the allergen-induced wheal 
formation. When the SPT was performed 24 hours after the XeCl laser irradiation, the size of 
the wheal induced by the allergen decreased by 7.8% at 0.5 x MED, by 35.2% at 1 x MED 
and by 55.3% at 2 x MED, as compared with that on the non-irradiated, control side. The 
inhibition was statistically significant at dosages of 1 x MED and 2 x MED (p<0.05). 2x MED 
caused a significantly higher decrease of the wheal size than 0.5xMED (p<0.05). When the 
SPT was performed 48 hours after the XeCl laser treatment, the inhibition of wheal formation 
was less than that obtained 24 hours after treatment, but on the 2 x MED laser irradiation, the 
wheal size was approximately 40% less than the size of the wheal on the non-irradiated 
control areas (Fig.2.). The XeCl laser irradiation had no effect on histamine-induced wheal 
formation (data not shown). 
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Fig. 2.: Effect of the 308 nm XeCl UVB irradiation on the SPT reaction. 
UVB irradiation suppresses the allergen induced wheal size. Values represent wheal size 24 and 48 hours after 
irradiation with different doses of UVB expressed as a percentage of the untreated control. Error bars represent 
the standard error of mean. Significant decreases were observed 24 hours after irradiation at lxMED and 
2xMED. Differences in wheal size were analyzed statistically by means of repeated measures one-way ANOVA 
followed by Dunnett's post-hoc test (n=7). Differences were considered to be statistically significant at p< 0.05. 
4.1.2. Effects of the UVA irradiation on the SPT reaction 
There was a tendency for decreasing of the wheal size in case of UVA irradiation. The 
strongest, statistically significant inhibition developed 72 h after the UVA treatment, it was 
20,36% at 0.5 J/cm2, 23,3% at 1 J/cm2 and 21,8% at 2 J/cm2 (p<0.05) (Fig.3.). No correlation 
was found between the inhibition of allergen-induced wheal formation and the UVA dose. 
140 
120 
O M 100 -
(M o 80 -
ON 
> — • 
60 -
.a V) 
13 40 -
i 20 -
0 -
UVA 
I I 
I I 0.5 J/cm2 
E ? ™ 1 J/cm2 
^ m 2 J/cm2 
24 48 
Hours 
72 
Fig. 3.: Effect of the UVA irradiation on the SPT reaction 
Values representing urtica size 24, 48 and 72 hours after irradiation with 0.5 1 and 2 J/cm2 are expressed as a 
percentage of the untreated control. Error bars represent the standard error of mean A significant decrease in 
urtica size was observed 72 h after the irradiation at 0.5 J/cm2, at 1 J/cm2 and at 2 J/cm . Differences in wheal 
size were analyzed statistically by means of repeated measures one-way ANOVA followed by Dunnet ts post-
hoc test. If parametric ANOVA was not applicable we used Friedman repeated measures ANOVA, followed by 
Dunnett's post-hoc test (n=5). Differences were considered to be statistically significant at p< 0.05. 
18 
4.1.3. Effects of the PUVA treatment on the SPT reaction 
The PUVA treatment suppressed the immediate-type hypersensitivity reaction in the skin in a 
dose-dependent manner. The inhibition was statistically significant at dosages of 1 J/cm2 48 
hours after the treatment and at 2 J/cm2 24, 48 and 72 hours after the irradiation (p<0.05). 
(Fig.4.) PUVA treatment did not influence the histamine-induced wheal formation. 
24 48 72 
Hours 
Fig. 4.: Effect of the PUVA treatment on the SPT reaction 
PUVA treatment suppresses the immediate-type hypersensitivity reaction in the skin in a dose-dependent 
manner. Values representing urtica size 24, 48 and 72 hours after irradiation with 0.5, 1 and 2 J/cm2 are 
expressed as a percentage of the untreated control. Error bars represent the standard error of mean. A 
significant decrease in urtica size was observed 24, 48 and 72 h after irradiation at 2 J/cm2 and also after 48 h at 
1 J/cm2. The statistical significance of the results was evaluated by repeated measures one-way ANOVA 
followed by Dunnett's post-hoc test; (n=5). Differences were considered to be statistically significant at p< 
0.05. 
4.1.4. Effects of combined UVA-UVB irradiation on the SPT reaction 
After UVA-UVB irradiation we observed a strong, statistically significant suppression of the 
immediate-type hypersensitivity reaction in the SPT. 24, 48 and 72 hours after the irradiation 
the inhibition of the wheal formation was statistically significant in case of any doses 
(p<0.05). Higher UV doses tended to cause a significantly stronger inhibition of the urtica 
formation than lower doses. (Fig.5.) 
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Fig. 5 . : . Effect of combined UVA-UVB irradiation on the SPT reaction 
Combined UVA-UVB irradiation resulted in a strong, statistically significant suppression of the immediate-type 
hypersensitivity reaction in the SPT. Values represent wheal size 24, 48 and 72 hours after irradiation with 0.214, 
0.428, 0.624 and 0.856 J/cm2 expressed as a percentage of the untreated control. Error bars represent the standard error 
of mean. Differences in wheal size were analyzed statistically by means of repeated measures one-way ANOVA 
followed by Dunnett's post-hoc test (n=10). Differences were considered to be statistically significant at p< 0.05. 
4.1.5. Effects of 8-MOP plus combined UVA-UVB irradiation on the SPT reaction 
The Geroxalen + combined UVA-UVB treatment induced a significant suppression of the 
urtica size in the SPT. The inhibition of the wheal formation was statistically significant at all 
of the applied dosages 24, 48 and 72 h after the treatment (p<0.05). In this case we couldn't 
observe so strong dose-dependent suppression of the immediate-type hypersensitivity 
reaction, but the strongest inhibition developed at 0.856 J/cm2 (Fig.6.). UV irradiation didn't 
influence the histamine induced wheal formation. 
Geroxalen + Combmed UVA-UVB 
100 
I I 0.2 J/cm2 
K X J 0.4 J/cm2 
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Fig. 6.: Effect of 8-MOP plus combined UVA-UVB irradiation on the SPT reaction 
The Geroxalen + combined UVA-UVB treatment induced a significant suppression of the urtica size in the SPT. 
Values represent wheal size 24, 48 and 72 hours after irradiation with 0.214, 0.428, 0.624 and 0.856 J/cm2 
expressed as a percentage of the untreated control. Error bars represent the standard error of mean. Differences 
in wheal size were analyzed statistically by means of repeated measures one-way ANOVA followed by 
Dunnett's post-hoc test (n=10). Differences were considered to be statistically significant at p< 0.05. 
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4.1.6. Effects of the VIS irradiation on the SPT reaction 
There was a tendency for decreasing of the wheal size in case of VIS irradiation, but VIS 
irradiation didn't influence significantly the wheal formation (Fig.7.). No correlation was 
found between the inhibition of allergen-induced wheal formation and the VIS dose. 
Dose (J/cm2) 
Fig. 7.: Effect of the VIS irradiation on the SPT reaction 
Irradiation with increasing doses of VIS light resulted in a slight, not significant inhibition of wheal formation. 
Values representing urtica size after irradiation with 2, 4, 6 and 8 J/cm2 are expressed as a percentage of the 
untreated control. Error bars represent the standard error of mean. The statistical significance of the results was 
evaluated by repeated measures one-way ANOVA followed by Dunnett's post-hoc test (n=7). 
4.1.7. Effects of the mUV/VIS irradiation on the SPT reaction 
Mixed irradiation with mUV/VIS light resulted in a dose-dependent inhibition of the allergen-
induced wheal formation (Fig.8.), the inhibition was statistically significant at the doses of 4 
J/cm2, 6 J/cm2 and 8 J/cm2 (p < 0.05) 24 hours after the treatment. When the skin prick test 
was performed 48 h after the mUV/VIS irradiation the size of the wheal induced by the 
allergen was decreased significantly at all of the applied dosages (p < 0.05). The two lowest 
doses did not produce erythema on the skin, the proportion of UVB light in mUV/VIS was 0.1 
J/cm2 for 2 J/cm2 and 0.2 J/cm2 for 4 J/cm2. The use of higher, erythematosus doses of 
mUV/VIS light (0.4 J/cm2 UVB for 8 J/cm2 mUV/VIS) led to almost complete inhibition of 
wheal formation. 
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Fig. 8.: Effect of the mUV/VIS irradiation on the SPT reaction 
Irradiation with increasing doses of mUV/VIS light resulted in a significant, dose-dependent inhibition of wheal 
formation in SPT. Values represent wheal size 24 and 48 hours after irradiation with increasing doses of 
mUV/VIS light expressed as a percentage of the untreated control. Error bars represent the standard error of 
mean. Differences in wheal size were analyzed statistically by means of repeated measures one-way ANOVA 
followed by Dunnett's post-hoc test (n=7). Differences were considered to be statistically significant at p< 0.05. 
4.2. Effects of phototherapy on the clinical symptoms of allergic rhinitis 
4.2.1. Effects of the low-dose XeCl laser treatment on the clinical symptoms of allergic 
rhinitis 
Of the 10 enrolled patients, 7 completed the 2-week treatment period. Three patients dropped 
out before completing the study, because of the significant worsening of their symptoms (lack 
of effect). Following treatment, there was no significant improvement in the sneezing, 
rhinorrhoea, nasal itching, nasal blockage or TNS (Fig.9.). The patients tolerated the 
treatment well, and no severe side effects were observed. Mild dryness of the nasal mucosa 
occurred in 2 patients; this did not need any intervention, and it disappeared within few days 
after the last treatment. 
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Fig. 9. Changes in the individual clinical symptoms and TNS during the low-
dose UVB treatment. 
No significant change was found (Wilcoxon's Sum of Ranks Test, n=7) in the nasal scores during the 2-week 
treatment period. 
4.2.2. Effects of the medium-dose XeCl laser treatment on the clinical symptoms of allergic 
rhinitis 
All eight patients enrolled in the medium-dose XeCl laser group completed the study. After 
the 2-week treatment period, significant improvements were observed in the sneezing, 
rhinorrhoea and nasal blockage scores, and also in the TNS (Fig. 10.). The improved clinical 
symptoms were usually first noted 4-5 days after the start of therapy, and thereafter the 
improvement was continuous. At the end of the XeCl laser treatment, the symptom scores 
were reduced by more than 50%. The XeCl laser treatment also reduced the severity of nasal 
itching, but the decrease was statistically not significant. No severe side effects occurred, but 
mild dryness of the nasal cavity was observed in 6 of the 8 patients; this was relieved by 
application of a vitamin A-containing oil. 
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Fig. 10.: Improvement in the individual clinical symptoms and TNS during 
the medium-dose UVB treatment. 
The clinical scores of sneezing, rhinorrhoea, nasal blockage and the TNS decreased significantly(p=0.018, 
p=0.035, p=0.013, respectively; Wilcoxon's Sum of Ranks Test, n=8) during the 2-week treatment period. 
4.2.3. Effects of the PUVA treatment on the clinical symptoms of allergic rhinitis 
Thirteen of the seventeen enrolled patients completed the study. Three subjects dropped out 
because of noncompliance and one because of a lack of efficacy. All the patients who 
completed the study responded well to the PUVA treatment. After the 3-week treatment 
period, significant improvements were observed in all of the nasal symptoms (sneezing, 
rhinorrhoea, nasal itching and nasal blocking) and also in the TNS (Fig. 11.). Fig. 12. shows 
the improvement of the TNS during the PUVA treatment in two patients with the change of 
the pollen number within the 3-week treatment period. The diagrams represent that the TNS 
were decreasing continuously due to the treatment, whereas the pollen number was still high. 
Mild dryness of the nasal mucosa was the only side-effect observed in three patients, this was 
easily overcome with vitamin A oil. 
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Fig. 11.: Improvement in the individual clinical symptoms and TNS 
during PUVA treatment of the nasal cavity. 
The clinical scores of sneezing, rhinorrhoea, TNS (p<=0.001), nasal itching and nasal blockage (p<=0.01) 
decreased significantly (Wilcoxon's Sum of Ranks Test, n=13) during the 3-week treatment period. Error bars 
represent the standard error of the mean. 
Fig. 12.: Improvement of the TNS during the PUVA treatment of the 
nasal cavity in two patients. 
The diagram also shows the change of the pollen number within the three-week treatment period. The diagrams 
represent that the total nasal scores were decreasing continuously due to the treatment, whereas the pollen 
number was still high. 
4.2.4. Effects of the mUV/VIS and 1-VIS treatment on the clinical symptoms of allergic 
rhinitis 
Forty-nine patients received intranasal irradiation either with mUV/VIS light (n=25, 
f:m=18:7, mean age: 37.8 years) or 1-VIS (n=24, f:m=15:9, mean age:39.3 years). The two 
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groups did not differ in age, disease duration or clinical scores at the beginning of treatment 
protocol. TNS significantly decreased after mUV/VIS (p = 0.004) and slightly increased after 
1-VIS treatment (p > 0.05) (Fig.l3.a.). In the mUV/VIS group the individual scores decreased 
compared to baseline for sneezing (p = 0.016), rhinorrhea (p = 0.007) and nasal itching (p = 
0.014). The scores for nasal obstruction improved slightly during phototherapy but changes 
did not reach statistical significance (p > 0.05) (Fig.l3.b.). In the control group, none of the 
scores improved significantly at the end of treatment. In fact, a significant increase was 
observed in the score for nasal obstruction (p = 0.017) (Fig.l3.b.). No improvement of nasal 
obstruction was recorded using acustic rhinometry (data not shown). 
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Fig. 13.: Effects of the mUV/VIS and 1-VIS treatment on the TNS and 
individual clinical symptoms of allergic rhinitis. 
TNS significantly decreased after mUV/VIS (p = 0.004) and slightly increased after 1-VIS treatment (p > 0.05) 
(Fig. 13.a.). In the mUV/VIS group the individual scores decreased compared to baseline for sneezing (p = 
0.016), rhinorrhoea (p = 0.007) and nasal itching (p = 0.014). The scores for nasal obstruction improved slightly 
during phototherapy but changes did not reach statistical significance (p > 0.05) (Fig.I3.b.). In the control 
group, none of the scores improved significantly at the end of treatment. In fact, a significant increase was 
observed in the score for nasal obstruction (p = 0.017) (Fig.l3.b.). 
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Fig. 14.: Scoring of the global outcome of treatment in mUV/VIS irradiated 
and control groups. 
In the overall efficacy assessment at the end of the treatment, mUV/VIS proved to be significantly more 
efficient than 1-VIS (p = 0.004) 
The therapy was well tolerated, the only side effect was dryness of the nasal mucosa, which 
occurred in all patients from the mUV/VIS group, and in 6 patients from the control group. 
All patients, except one from the mUV/VIS group, scored the dryness as mild. In these 
patients dryness was controlled with emollients. In one patient who scored the dryness as 
severe the treatment was stopped. 
The drop out rates in the active treatment versus the control group did not differ. In the 
mUV/VIS group we had 5 drop-outs (one because of lack of efficacy, one because of dryness 
of the mucosa, one for lack of compliance and 2 because of a modified holiday schedule). In 
the control group we had 4 drop-outs (2 in consequence of lack of efficacy, one for lack of 
compliance and one because of an upper respiratory infection). In the control group a 
significantly higher consumption of rescue medication was recorded compared to the 
mUV/VIS group (93 tablets in the control group versus 57 tablets in the mUV/VIS group). 
27 
5. Discussion 
5.1. Mechanism of the UV light induced immunnosuppression 
UV irradiation has been successfully used for the treatment of hyperproliferative and 
inflammatory skin diseases for many years. Initially, BB-UV light sources in the UVB range 
290-320 nm were used for such treatment, but during the last few years these light sources 
have been replaced with the more efficient NB-UVB light sources operating at 310-313 nm 
[15]. We recently introduced new, highly effective XeCl excimer laser-based UVB 
phototherapy for the treatment of different skin diseases [19, 37-39]. The XeCl laser was 
found to be more effective than conventional UVB light sources in the phototherapy of skin 
disorders [22, 37]. These results have been confirmed by other groups and the 308 nm 
excimer laser is currently widely used for the treatment of skin diseases [25, 26]. UVA 
irradiation, 8-MOP plus UVA radiation, combined UVB-UVA and high-dose UVA1 therapies 
also have been used for an expanding number of indications in dermatological practice due to 
their immunosuppressive and immunomodulatory effects. UV light influences different 
inflammatory and immunological processes: it inhibits the delayed-type hypersensitivity 
reaction; reduces the number of Langerhans cells and induces alterations in the activity of 
epidermal antigen-presenting cells (APC) [28, 40] UV exposure activates T-suppressor cells 
and keratinocytes, which produce a wide variety of cytokines, such as IL-10. These cytokines 
modulate the APC function and other immunological processes [27, 30, 31, 33, 34, 41-43]. It 
has been demonstrated previously that UV radiation induces keratinocyte and T-cell apoptosis 
[22, 32] and UV radiation is known to modulate the expression of adhesion molecules on 
Langerhans cells and keratinocytes [14, 33, 41, 44, 45]. UV irradiation suppresses histamine 
release from mast cells [46] and decreases the number of infiltrating eosinophils in the skin. 
5.2. Pathomechanism of allergic rhinitis 
All of these inflammatory cells and processes are important in the pathogenesis of allergic 
rhinitis, which is an allergen-induced, IgE-mediated inflammatory disease of the nasal 
mucosa. During sensitization in the nasal mucosa allergen is taken and presented by antigen 
presenting cells (dendritic cells) to the T-helper cells. This process activates Th2 cells in 
atopic patients, these cells produce a variety of cytokines (IL-4, IL-13). By the effect of these 
mediators B lymphocytes become activated, and produce IgE antibodies, which have a central 
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role in the allergic reaction. The produced allergen specific IgE binds to IgE receptors (FceRI 
and FceRII) present on the surface of mast cells, eosinophils and dendritic cells. 
In the elicity phase allergen binds to the allergen specific IgE molecules fixed to the FceRI and 
FceRII receptors on the surface of these cells, by the effect of this process effector cells will be 
activated. In the course of the mast cell activation histamine and other preformed inflammatory 
mediators are released. Histamine binds to HI receptors and produces the specific allergic 
symptoms. This is the early or histamine dependent phase. Due to the mediators (IL-4, IL-5) 
produced and released by mast cells, other cells (eosinophils, macrophages, T-cells and 
basophils) migrate to the nasal mucosa and the inflammatory process is amplified. This is the 
late phase of the allergic reaction, which begins 6-12 hours after the allergen exposition. The 
eosinophils are very active effector cells during the cellular infiltration. Eosinophils-from the 
circulation- bind to vascular endothelium by the effect of IL-5, as a result of this process their 
migration and function is amplified. Some of the mediators released from mast cells have 
leukocyte chemotactic activity, so these mediators promote leukocyte migration to the site of 
the inflammation. Arriving to the site of inflammation the activated eosinophils release a variety 
of inflammatory mediators to the extracellular compartment. IL-3, IL-5 and 
granulocyte/macrophage colony-stimulating factor (GM-CSF) promote the differentiation of the 
eosinophils, and via inhibition of their apoptosis elongate the eosinophil survival. The longer 
eosinophil survival is essential in the chronic allergic inflammation. In the course of the 
basophil degranulation histamin is released, too, so basophils take part in the early and in the 
late phase allergic responses, too. The cytokines of the T-helper cells promote eosinophil 
differentiation and elongate eosinophil survival [11,47]. 
5.3. Mechanism of the UV light induced suppression of the immediate type 
hypersensitivity reaction in the skin 
UV therapy has long been used in the treatment of different inflammatory skin diseases, and 
as there are many common pathogenetic factors in these skin disorders and allergic rhinitis, 
we have now addressed the question of whether phototherapy might also be effective for the 
treatment of hay fever. 
The SPT is a method that is widely used to investigate the immediate hypersensitivity reaction 
to a specific allergen in the skin, and it has been shown that there is a good correlation 
between the SPT reaction and the nasal symptoms in patients with allergic rhinitis. So in the 
first series of our study we investigated the effects of the different kind of irradiations on the 
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immediate-type hypersensitivity reaction in the skin in order to identify the wavelengths, 
which are able to suppress most effectively the clinical symptoms of allergic rhinitis. 
There was a tendency for decreasing of the wheal size in case of VIS irradiation, but VIS 
irradiation didn't influence significantly the wheal formation. By the effect of the UVA 
irradiation a tendency for decreasing of urtica formation was also observed, the suppression 
was statistically significant only 72 hours after the treatment. The UVB irradiation with the 
308 nm XeCl excimer laser and the PUVA treatment suppressed the allergen-induced wheal 
development in a dose-dependent manner, the inhibition was statistically significant at 
erythematous doses. The fact that the XeCl laser and PUVA treatment had no effect on 
histamine-induced wheal formation suggests that the XeCl laser and PUVA treatment inhibit 
histamine release from the mast cells. Our data are in good accord with other findings 
suggesting that UV irradiation significantly reduced the size of the allergen induced wheal in 
the SPT [28, 48, 49]. Vocks et al. found that a single dose of UVB irradiation significantly 
reduced the allergen induced wheal size in the SPT, while the flare responses decreased 
significantly only after three suberythematous UVB irradiations. Whole body UVB 
irradiation, excluding the prick test areas didn't influence significantly the wheal and flare 
responses to common aeroallergens, suggesting that the UVB-irradiation induced inhibition of 
histamine release is a local effect of the UVB light [49]. Fjellner et al. demonstrated that 
moderate doses of UVB irradiation inhibited the histamine-release effect of compound 48/80 
from rat peritoneal mast cells in vitro, while higher doses of UVB light caused cytotoxic 
histamine leakage from the mast cells [50]. UVB irradiation was also capable of inhibiting 
compound 48/80-induced mast cell degranulation in both mice and humans[51, 52]. 
In another study Fjellner et al. found that repeated PUVA treatment of human skin was 
followed by decreases in the itch and flare responses induced by intradermal injection of the 
histamine-liberating agent compound 48/80 [50]. They presumed that the inhibition of 
histamine release from mast cells by PUVA might be explained by a membrane-stabilizing 
effect in the mast cells. Danno et al. also investigated the effect of the PUVA treatment on 
the immediate type hypersensitivity skin reaction. An animal model was used for this study. 
Mouse ears were treated with 8-MOP solution plus UVA radiation. After PUVA treatment 
mast cell liberators, such as concanavalin-A, compound 48/80, and a vasodilator mixture 
including 5-hydroxytryptamine and histamine were injected intradermally. After this ear 
swelling response, the rate of the mast cell degranulation, and mast cell numbers were 
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measured. They found that PUVA treatment significantly suppressed the compound 48/80 and 
concanavalin-A induced ear swelling response and the mast cell degranulation [51]. In 
another experiment they found that subedematous doses of UVB radiation significantly 
suppressed the mouse ear swelling response and the mast cell degranulation evoked by 
intradermal injection of compound 48/80 [51]. All these results suggest that the inhibition of 
histamine release from mast cells by UVB irradiation and PUVA treatment is probably 
mediated by a direct membrane stabilization effect. 
The combined UVA-UVB irradiation, the Geroxalen plus combined UVA-UVB treatment 
and the mUV/VIS irradiation caused a strong, statistically significant, dose-dependent 
inhibition of the SPT in suberythematosus doses, too. These results suggest that these 
combined irradiations have a more profound and rapid inhibitory effect on immediate type 
skin reaction than UVB or 8-MOP plus UVA alone. The underlying mechanism might be the 
synergistic effect of different wavelengths on histamine release. 
In the SPT, the antigen induces a rapid release of histamine from the sensitized cells and 
results in the development of a wheal in 10-20 minutes. It has been shown that UVA light 
significantly inhibited histamine release from human basophils and a human mast cell line 
and that UVB light had an inhibitory effect only on mast cells [46], The effect of in vitro 
UVA irradiation of basophils is characterized by a biphase dose dependent action on 
histamine release: low doses are followed by a significant inhibitory effect, in contrast high 
doses are followed by histamine eliberation [53] The strong inhibition of SPT reaction by 
combined UVA-UVB, Geroxalen plus UVA-UVB and mUV/VIS irradiation might therefore 
be explained by the combined actions of the different wavelengths on the skin mast cells. 
5.4. Possible mechanisms of rhinophototherapy 
According to the SPT results in the second series of our study we investigated the effects of 
different light sources in the treatment of allergic rhinitis. At first we used the biologically 
most effective UVB light source, the 308 nm XeCl excimer laser to assess the efficacy of 
phototherapy in hay fever, and we found that intranasal UVB phototherapy with medium-dose 
308 nm XeCl excimer laser significantly suppressed the nasal symptoms of patients with 
severe hay fever, whereas in low dosages had no effect on the symptoms. For the treatment of 
skin diseases with NB-UVB irradiation, the therapy is started usually with a UVB dose of 0.8 
x MED dose, which is gradually increased, depending on the patient's tolerance, and 
irradiation is performed 3-4 times weekly [15]. Since the XeCl excimer laser is more 
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Our group also investigated the effect of the mUV/VIS and 1-VIS light on eosinophils and 
inflammatory mediators in the nasal lavage, on T-cell, eosinophil and RBL-2H3 cell apoptosis 
and on the mediator release from RBL-2H3 cells. Koreck et al [57] found that in the 
mUV/VIS group the percentage of eosinophils and the ECP level in the nasal lavage 
decreased significantly during therapy, whereas, both the eosinophil cell count and the ECP 
level increased slightly in the control group. The nasal fluid IL-5 levels decreased after 
treatment in the mUV/VIS group and increased in the control group; as concerns the changes 
from the mean baseline values the difference between the two groups was statistically 
significant. A slight decrease of IL-4 levels was observed in nasal lavages from patients 
treated with mUV/VIS light and a slight increased in the samples from the control group, but 
changes did not reach statistical significance. mUV/VIS irradiation induced a dose-dependent 
increase in both, apoptotic T cells and eosinophils. No pro-apoptotic effect of 1-VIS 
irradiation was observed in either T cells or eosinophils. Moreover, a dose dependent increase 
of both CD3+CD45RO+ and CD3+CD45RA+ was observed after mUV/VIS irradiation. RBL-
2H3 cells were resistant to mUV/VIS induced apoptosis. 
We found that following mUV/VIS irradiation the P-hexosaminidase release was inhibited. 
Even low doses of mUV/VIS (15 - 60 mJ/cm2) induced a significant decrease of P-
hexosaminidase release and higher doses (240 mJ/cm2) had a complete blocking effect. In 
contrast, no inhibitory effect of 1-VIS irradiation was observed. 
Allergic inflammation is associated with a shift in the cytokine balance towards a Th2 
predominance [7]. Several data indicate that Th2 cytokines (IL-5 and IL-4) are present in 
increased amounts in the nasal mucosa of allergic rhinitis patients [6, 7]. IL-5 is a cytokine, 
which promotes the maturation, activation and prolonged survival of eosinophils, the main 
effector cells in hay fever [58]. The suppression of prolonged eosinophil survival induced by 
IL-5 is a potential therapeutic strategy for the resolution of allergic rhinitis. In our study 
irradiation of the nasal mucosa resulted in a significant decrease in local IL-5. T lymphocytes 
are major sources of IL-5 [59]. Thus, apoptosis of these cells following phototherapy might be 
the basis of the underlying mechanism of decreased IL-5 production. Memory T cells have an 
important role in the perpetuation and maintenance of allergic process. Apoptosis of these 
cells following phototherapy might have a long-term beneficial effect. Phototherapy also 
resulted in a decreased number of eosinophils and a decreased level of ECP in the naiSal 
lavage fluid. This might be attributed to the direct pro-apoptotic effect of mUV/VIS on 
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eosinophils and to the decreased local IL-5 level. Similar results concerning eosinophil, ECP 
and IL-5 levels and T lymphocytes are observed after other well-established therapies of 
allergic rhinitis, such as topical glucocorticoids or immunotherapy [6, 36, 60, 61]. Allergic 
rhinitis is also accompanied by an elevated level of IL-4 in the nasal mucosa. IL-4 is essential 
in promoting the commitment of T cell precursors to produce Th2 cytokines and it activates 
the IgE isotype switching of B cells [5]. However, the role of IL-4 in modulating eosinophil 
survival and function is not yet clear. IL-4 could regulate the production of CCL11/eotaxin, a 
potent eosinophil chemoattractant promoting tissue eosinophilia, but it is also an inducer of 
apoptosis of peripheral blood eosinophils [62, 63]. The pro-apoptotic effect of IL-4 is more 
dramatic in eosinophils separated from atopic individuals as compared with those from 
nonatopic subjects. Wedi et al. have suggested that IL-4 mediated eosinophil apoptosis may 
be of physiological relevance if the eosinophil is not primed by the survivor cytokines (IL-5, 
IL-3 or GM-CSF) [63]. These data suggest that the quantitative relation of IL-4 and IL-5 
produced during inflammation may determine the apoptosis rate of eosinophils at the site of 
allergic inflammation. Our study did not reveal significant changes in IL-4 levels in the nasal 
lavage samples. Similar results were reported after topical glucocorticoid therapy of allergic 
rhinitis [64], Thus, the reduction of IL-5 in nasal mucosa after phototherapy together with the 
persistence of IL-4 might further promote phototherapy induced eosinophil apoptosis. 
Not only T cells and eosinophils, but also mast cells and basophils have important roles in the 
effector phase of the allergic reaction [9]. They are the principal source of different mediators 
and especially of histamine. The role of histamine in allergic rhinitis has been well studied 
and is mirrored by the wide use of antihistamines in the treatment of allergic rhinitis [65]. In 
our study, we demonstrated that mUV/VIS irradiation is able to inhibit mediator release from 
RBL-2H3 cells. It has been shown that ^-hexosaminidase release following allergen challenge 
of RBL-2H3 cells passively sensitized to murine IgE correlates with histamine release and 
SPT [66]. Several other therapeutic agents used for the therapy of allergic rhinitis and asthma 
have been already tested in this in vitro model of histamine release, and have been shown to 
be potent in inhibiting IgE-mediated histamine release [67, 68]. Our findings are in 
concordance with previous studies in which the inhibitory effect of UVA and UVB light on 
histamine release was assessed [53]. The use of mUV/VIS, which is characterized by low 
dose UVA and low dose UVB is followed by a very strong inhibitory effect, and in fact a 
complete blocking effect could be achieved at certain doses. 
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The data reported here demonstrate that phototherapy was able to inhibit the effector phase of 
the allergic reaction at multiple checkpoints. In contrast with antihistamines, which influence 
predominantly histamine-mediated features of the allergic process, phototherapy has a 
different, more complex action spectrum. This suggests that intranasal phototherapy might be 
an alternative for patients not controlled by antihistamines. Our data support this indication 
considering that all enrolled patients were non-responders to conventional therapies, including 
the latest generation of antihistamines. 
5.5. Possible side effects 
It is well known that repeated high-dose ultraviolet light irradiation has carcinogenic potential. 
The ultraviolet light-induced carcinogen effect is linked to the cumulative doses of the 
ultraviolet light (usually requiring many years). For PUVA treatment there is a higher risk for 
cancer development among patients that have received more than 260 PUVA treatments with a 
cumulative dose of between 100 - 500 J/cm2 [69]. If long wave-UVA (340 - 400 mJ/cm2) is 
used alone - without previous photosensitization - for the treatment of skin disorders, usually 
much higher UV dosages are used. For example, for the treatment of atopic dermatitis 
wavelengths between 340-400 nm are used with an effective dose between 50-100 J/cm per 
t 
treatment. This results in a cumulative dose of 750 j/cm over a three-week treatment period 
[70]. Since the irradiation dosages for the phototherapy or photo-chemotherapy of the nasal 
mucosa uses much lower cumulative dose than the threshold for increased cancer risks, the 
probability of carcinogenesis in the present therapeutically schemes is extremely low. 
Similarly as for topical corticosteroids used for the treatment of the disease, UV light by its 
immunosuppressive effect might facilitate the appearance of viral and bacterial infections on 
the treated areas. However, the likelihood for this is lower than that of the presently used local 
immunosuppressants since ultraviolet light has a direct anti-microbial effect. We did not 
observe any infections during this study. 
Phototherapy of the nasal cavity was tolerated well, in fact the only side effect observed-
similarly as for locally applied corticostreroids- was mild dryness of the mucosa which 
occurred at 50% of patients during the duration of the treatment. This symptom was easily 
overcome with vitamin A oil, except one patient from the mUV/VIS group, who scored the 
dryness of the nasal mucosa as severe and the treatment was stopped. 
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6. Summary 
Hay fever is a very common allergic disorder, its prevalence is about 8,1% among the 
children, 21% among the adolescents and 11% among the adults in Hungary [71]. The 
treatment of allergic rhinitis is a complex problem, including the elimination of the inhalative 
allergens from the patient's environment, the specific pharmacotherapy and immunotherapy. 
However in a lot of cases patients don't respond well to the conventional antiallergic 
treatment or the drug therapy is contraindicated, and the combined pharmacotherapy has a 
numerous side-effects, so every new therapeutic tool is therefore of great importance. 
Since UV irradiation has been shown to exert both local and systemic immunosuppression 
and is effectively used in the treatment of several immune mediated skin diseases, we were 
interested in whether phototherapy might also be effective for the treatment of allergic 
rhinitis. Since there is a good correlation between the suppression of the reaction in SPT and 
inhibition of the clinical symptoms, firstly we investigated the effect of different wavelengths 
UV irradiations to inhibit the wheal formation in the SPT reaction. We found that irradiation 
with the 308 nm XeCl excimer laser, PUVA, the combined UVA-UVB, Geroxalen plus 
UVA-UVB treatment and irradiation with mUV/VIS light significantly inhibited the allergen 
induced immediate type hypersensitivity reaction in the skin, while UVA and VIS irradiation 
didn't influence significantly the SPT reaction. Based on these results we tested the effect of 
these different light sources in the treatment of allergic rhinitis, and we found that 
phototherapy of the nasal cavity with medium dose 308 nm XeCl excimer laser, 8-MOP plus 
UVA, or mUV/VIS light resulted in a significant improvement of the clinical symptoms of 
allegic rhinitis. Phototherapy was tolerated well; the only side effect was the slight dryness of 
the nasal mucosa. In conclusion, our findings indicate that phototherapy represents an 
efficient therapeutic modality for the treatment of patients suffering from allergic rhinitis. 
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